It has been reported that small molecule inhibitors of EGFR, such as lapatinib, erlotinib, gefitinib and cetuximab, can prevent the growth and progression of HNSCC and decrease the expression of stem cell-related molecule. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.